173 related articles for article (PubMed ID: 14742572)
1. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
Larsson C; Holmgren J; Lindahl G; Bergquist C
Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
[TBL] [Abstract][Full Text] [Related]
2. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
3. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
4. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 1999 Feb; 17(5):454-8. PubMed ID: 10073723
[TBL] [Abstract][Full Text] [Related]
5. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
[TBL] [Abstract][Full Text] [Related]
6. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
[TBL] [Abstract][Full Text] [Related]
7. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Infect Immun; 1996 Sep; 64(9):3518-23. PubMed ID: 8751893
[TBL] [Abstract][Full Text] [Related]
8. Development of experimental GBS vaccine for mucosal immunization.
Gupalova T; Leontieva G; Kramskaya T; Grabovskaya K; Bormotova E; Korjevski D; Suvorov A
PLoS One; 2018; 13(5):e0196564. PubMed ID: 29727446
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
Price GA; Russell MW; Cornelissen CN
Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Adv Exp Med Biol; 1997; 418():851-3. PubMed ID: 9331786
[No Abstract] [Full Text] [Related]
11. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
12. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
Wu HY; Russell MW
Infect Immun; 1993 Jan; 61(1):314-22. PubMed ID: 8418053
[TBL] [Abstract][Full Text] [Related]
13. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
[TBL] [Abstract][Full Text] [Related]
14. Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.
Katz J; Harmon CC; Buckner GP; Richardson GJ; Russell MW; Michalek SM
Infect Immun; 1993 May; 61(5):1964-71. PubMed ID: 8478086
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections.
Dale JB; Chiang EC
J Infect Dis; 1995 Apr; 171(4):1038-41. PubMed ID: 7706785
[TBL] [Abstract][Full Text] [Related]
17. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.
Stålhammar-Carlemalm M; Waldemarsson J; Johnsson E; Areschoug T; Lindahl G
Cell Host Microbe; 2007 Dec; 2(6):427-34. PubMed ID: 18078694
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system.
Harokopakis E; Hajishengallis G; Michalek SM
Infect Immun; 1998 Sep; 66(9):4299-304. PubMed ID: 9712781
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
Relf W; Hayman W; Russell-Jones G; Good M
Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
[No Abstract] [Full Text] [Related]
20. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
